Sai Life Sciences Limited
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Revenue grew 15.7% YoY
Concerns1
- Low return on equity of 9.4%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 7 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.64 K Cr | β | βΉ173.00 Cr | β | β | 8.0% | 15.7% | 82.1% |
| Mar 2024 | βΉ1.42 K Cr | β | βΉ95.00 Cr | β | β | 9.4% | 22.6% | 295.8% |
| Mar 2023 | βΉ1.16 K Cr | β | βΉ24.00 Cr | β | β | 2.6% | 37.6% | 50.0% |
| Mar 2022 | βΉ841.00 Cr | β | βΉ16.00 Cr | β | β | 1.8% | 12.0% | -75.4% |
| Mar 2021 | βΉ751.00 Cr | β | βΉ65.00 Cr | β | β | 7.5% | 3.6% | -18.8% |
| Mar 2020 | βΉ725.00 Cr | β | βΉ80.00 Cr | β | β | 10.1% | 4.3% | 9.6% |
| Mar 2019 | βΉ695.00 Cr | β | βΉ73.00 Cr | β | β | 10.2% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,005 |
| Total Expenses | 1,487 |
| EBIT / Operating Profit | 518 |
| OPM % | 26% |
| Other Income | 44 |
| Finance Costs | 49 |
| Depreciation & Amortisation | 136 |
| Profit Before Tax | 377 |
| Tax % | - |
| Net Profit / PAT | 282 |
| EPS (βΉ) | 13.52 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Sai Life Sciences Limitedthis co. | βΉ19.11 K Cr | βΉ1.64 K Cr | 67.70 | 8.23 | 62.41 | 15.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |